Tulavi Therapeutics
PrivateLast Round
Series C
Jul 15, 2025
Est. Valuation
$83M
Total Funding Raised
$34.34M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Tulavi Therapeutics is a medical devices & equipment company that develops absorbable hydrogel-based technologies to optimize nerve recovery and reduce the risk of neuroma formation.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Tulavi Therapeutics Comparables
Compare Tulavi Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Renerva, Inc. | 64% | |
| Alafair Biosciences, Inc. | 63% | |
| Stryker Corporation | 61% |
Tulavi Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jul 15, 2025 | ||||
| Series B | Dec 16, 2021 | ||||
| Series A | Feb 27, 2021 | ||||
| Seed | May 8, 2020 | ||||
| Series A | Apr 26, 2018 |
Tulavi Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ascension Ventures | Seed, Series B, Series A |
| Greenwave Ventures | Series B, Series C |
| NeuroTechnology Investors | Series B |
| Delos Capital Partners | Seed, Series A |
| Medical Technology Enterprise Consortium | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 33% MoM, from 1.5K to 2K.
- Aug 1, 2026
Grew 26% QoQ, from 39 to 49 employees.
Recent news
Latest coverage and updates
- is_developingAug 14, 2026
Tulavi Therapeutics, Inc. is developing medical animation illustrating the use of the Allay Gel Cap for neuroma treatment on Aug 14th '26.
Tulavi Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Tulavi Therapeutics's valuation, stock price, and market status.
Is Tulavi Therapeutics a public or private company?
Tulavi Therapeutics is a private company.
What is the current stock price of Tulavi Therapeutics?
Tulavi Therapeutics is a private company, so its shares have no public market price. Caplight tracks Tulavi Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Tulavi Therapeutics worth (valuation)?
Tulavi Therapeutics's valuation is estimated at $83.0M based on funding round data.
Can I buy Tulavi Therapeutics stock?
Tulavi Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Tulavi Therapeutics's last funding round?
Tulavi Therapeutics's most recent funding round was Series C on July 15, 2025.
Who are the main investors in Tulavi Therapeutics?
Key investors in Tulavi Therapeutics include Greenwave Ventures.
Will Tulavi Therapeutics IPO soon?
No public IPO plans have been announced for Tulavi Therapeutics.
How can I track Tulavi Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Tulavi Therapeutics's shares on secondary markets.